A detailed history of Goodwin Investment Advisory transactions in Eli Lilly & CO stock. As of the latest transaction made, Goodwin Investment Advisory holds 263 shares of LLY stock, worth $209,261. This represents 0.1% of its overall portfolio holdings.

Number of Shares
263
Previous 250 5.2%
Holding current value
$209,261
Previous $226,000 3.1%
% of portfolio
0.1%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$772.14 - $960.02 $10,037 - $12,480
13 Added 5.2%
263 $233,000
Q1 2024

May 06, 2024

BUY
$592.2 - $792.28 $148,050 - $198,070
250 New
250 $194,000
Q3 2022

Nov 14, 2022

BUY
$296.48 - $337.87 $73,823 - $84,129
249 New
249 $81,000
Q2 2022

Aug 16, 2022

SELL
$278.73 - $327.27 $69,403 - $81,490
-249 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$234.69 - $291.66 $58,437 - $72,623
249 New
249 $71,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Goodwin Investment Advisory Portfolio

Follow Goodwin Investment Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goodwin Investment Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Goodwin Investment Advisory with notifications on news.